Novel Lymphoma Targets/Agents
In session VI of iwNHL 2018, John Kuruvilla, MD, FRCPC, Ryan Wilcox, MD, Francisco Hernandez Ilizaliturri, MD, Laurie Sehn, MD, and Kieron Dunleavy, MD, discussed a variety of novel therapy options.
Presentations
Princess Margaret Cancer Centre, Toronto, Canada
John Kuruvilla, MD, FRCPC from Princess Margaret Cancer Centre, Toronto, Canada, gives a talk on selinexor, an investigational anti-cancer agent targeting nuclear export.
University of Michigan Rogel Cancer Center, Ann Arbor, MI
Ryan Wilcox, MD, from University of Michigan Rogel Cancer Center, Ann Arbor, MI, speaks on the clinical activity of cerdulatinib in non-Hodgkin lymphoma.
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Francisco Hernandez Ilizaliturri, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the role of MCL-1 in B-cell malignancies.
British Columbia Cancer Centre for Lymphoid Cancer, Canada
Laurie Sehn, MD, from British Columbia Cancer Centre for Lymphoid Cancer, Canada, talks about the potential use of polatuzumab vedotin in treating non-Hodgkin lymphoma,
George Washington University, Washington, DC
Kieron Dunleavy, MD, from George Washington University, Washington, DC, speaks on the therapy options for MYC-positive, double-hit and triple-hit diffuse large B-cell lymphoma (DLBCL).
